JNJ.BA Johnson & Johnson Co DRC

Healthcare Pharmaceuticals Buenos Aires Exchange
30,320 ARS
Close of Oct 29, 2026
18,310 30,320
Market cap
ARS 365T
P/E
16.0x
P/B
2.88x
ROE
18.0%
Dividend yield
-
Fundamental score
2.9/5

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is JNJ.BA undervalued?

Graham number
Price30,320
Graham value21,235
Premium42.8%

JNJ.BA trades 42.8% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Johnson & Johnson Co DRC fundamental analysis

15 of 22 checks passed

ROE 1/2

Moderate return on equity (18.0%), between 10% and 20%.

ROA 1/1

Return on assets (7.4%) is above the industry median (5.6%).

Profit Consistency 2/2

Profitable for 8 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (90.5%) is above the 5-year average (14.8% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (90.5%) is above the industry median (-3.6%).

Revenue Growth 0/2

Revenue shrank 0.3% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (43.9%), up to 100%.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 17.6x against interest expense, well covered.

PE vs Market 0/1

PE (16.0x) is above the market median (6.7x).

PE vs Industry 0/1

PE (16.0x) is above the industry median (5.8x).

PBV 0/1

Price to book (2.9x) is above the industry median (0.8x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 45.9, limit 22.5).

PEG 0/1

PEG on 5-year earnings growth is 1.08, above 1.

Dividend Yield 1/2

Dividend yield (2.9%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 1/2

Dividends paid without a cut of more than 10% for 8 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 46.2%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Johnson & Johnson Co DRC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Johnson & Johnson Co DRC

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers,…

Full company profile